BioSpace News Archive

LIXTE Biotechnology Holdings, Inc. announced the closing of its previously announced registered direct offering of 583,334 shares of common stock and concurrent private placement of common warrants to purchase up to 583,334 shares of common stock at a purchase price of $6.00 per common share, priced “at-the-market” under Nasdaq rules.

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended June 30, 2023.

Champions Oncology, Inc. will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023, after the U.S. financial markets close.

Bio-Rad Laboratories, Inc. announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 3, 2023, following the release of its second quarter 2023 financial results.

ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced a series of leadership changes and appointments, designed to ensure a seamless transition into the next stage of growth for the company.

Ardelyx, Inc. (Nasdaq: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present on behalf of the company at the virtual H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 2:00 P.M. Eastern Time.

Codexis, Inc. announced that, in alignment with its previously announced strategy to focus resources on programs with the strongest probability of creating significant value in the near-term and beyond, the Company intends to prioritize the advancement and commercialization of its Enzyme-Catalyzed Oligonucleotide Synthesis™ platform and its highly complementary Pharmaceutical Manufacturing business.